CJC-1295 Human Studies: What the Evidence Actually Shows
CJC-1295 has one solid human study, and it proves a narrower point than most people assume. Here is what it actually showed, and what it did not.
Human hormone study
GH and IGF-1 rose
Outcome trials
None
Form (DAC vs not)
Changes everything
Mechanism
Established GHRH analog
One good study, proving one specific thing
CJC-1295 is a long-acting GHRH analog that signals the pituitary to release growth hormone. Its human evidence is real but narrow.
The core point: the human study proved CJC-1295 raises growth hormone and IGF-1 and keeps them up for days. It did not measure muscle, fat or performance. The popular claims live in that unmeasured gap.
What has been studied, and how strong it is
Solid on hormone levels, silent on real-world outcomes.
-
Human pharmacology
Sustained GH and IGF-1 rise
In healthy adults, a single dose of CJC-1295 with DAC raised growth hormone and IGF-1 and kept them elevated for days, confirming the long-acting mechanism.
Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683)
-
Mechanism and form
DAC is what makes it last
The Drug Affinity Complex extends half-life, giving the days-long elevation. Without DAC (often sold as Mod GRF 1-29) it is short-acting. Most product sold as CJC-1295 is the no-DAC version, so the form changes what any claim means.
-
The gap
Outcome trials
No controlled human trial has measured body composition, strength, recovery or metabolic endpoints for CJC-1295. The evidence stops at hormone levels, so outcome claims are extrapolation.
It raises the hormones, the rest is inference
CJC-1295 is better evidenced than many peptides on one narrow point: it reliably and durably raises GH and IGF-1 in people. That is a real, measured human result.
Whether that translates into the muscle, fat-loss and recovery benefits people want is not something any human trial has tested, and raising GH is not automatically beneficial or risk-free. Add the DAC-versus-no-DAC confusion, and the honest read is a proven hormonal effect wrapped in unproven outcome claims.
Where CJC-1295 stands in the US
Research chemical, with no compounding pathway.
CJC-1295 is not FDA-approved and was not among the peptides in the October 2026 HHS compounding policy. It is sold only as a research chemical, for laboratory use, not for human consumption. Full picture on the CJC-1295 profile.
Frequently asked questions
Has CJC-1295 been tested in humans?
Yes, in a limited way. The key human study was a pharmacology trial showing that CJC-1295 with DAC raised growth hormone and IGF-1 levels in healthy adults and kept them elevated for days after a single dose. That establishes it does what a long-acting GHRH analog is supposed to do, but it is a hormone-level study, not a trial of real-world outcomes.
What did the human study show?
A single injection of CJC-1295 with DAC produced sustained increases in growth hormone secretion and IGF-1 in healthy adults, lasting well beyond a day thanks to the molecule's long half-life. It confirmed the mechanism and the long duration; it did not measure muscle, fat, strength or any clinical endpoint.
Does raising GH and IGF-1 mean it builds muscle or burns fat?
Not necessarily, and that is the limit of the evidence. The human study measured hormone levels, not body composition or performance. Higher GH and IGF-1 are plausibly linked to those outcomes, but no controlled human trial has shown CJC-1295 produces them, so the body-composition claims are extrapolation.
What is the difference between CJC-1295 with and without DAC?
DAC (Drug Affinity Complex) is a modification that greatly extends half-life, giving the days-long GH elevation seen in the human study. Without DAC, the compound (often sold as Mod GRF 1-29) is short-acting and dosed more like a pulse. Much of what is sold as CJC-1295 is actually the no-DAC version, so the form matters when reading any claim.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved for any indication and was not among the peptides covered by the October 2026 HHS compounding policy. It is sold only as a research chemical, for laboratory use, not for human consumption.
What is missing from the evidence?
Controlled human trials measuring real outcomes, body composition, strength, recovery or metabolic markers, rather than just hormone levels, and doing so for the specific form being used. Until those exist, CJC-1295's human evidence stops at proof that it raises GH and IGF-1.
Track your protocol with the evidence in view
Log doses, IGF-1 and how you feel in one place, and keep claims tied to what is measured. Free.
Sources
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683
This content is for informational purposes only and is not medical advice. CJC-1295 is not FDA-approved in the United States and was not included in the October 2026 HHS peptide compounding policy. Its human evidence is limited to hormone-level pharmacology, not clinical outcomes. Research-grade CJC-1295 is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider.